找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2; A Multidisciplinary Siguna Mueller Book 2023 The Editor(s) (if applicabl

[復(fù)制鏈接]
樓主: Inoculare
21#
發(fā)表于 2025-3-25 04:53:55 | 只看該作者
22#
發(fā)表于 2025-3-25 10:42:06 | 只看該作者
https://doi.org/10.1057/9781403919618Arguably, mRNA vaccines have led to risks and concerns that previously were not anticipated. Both the vaccine by Pfizer and that by Moderna are now linked to post-vaccination deaths and many adverse health effects
23#
發(fā)表于 2025-3-25 11:40:25 | 只看該作者
24#
發(fā)表于 2025-3-25 16:39:40 | 只看該作者
Relevance for mRNA Vaccine SafetyThis chapter describes how the above unsubstantiated assumptions underlying mRNA vaccines may impact vaccine safety. Again, the analysis here is done in a more general way, aiming to uncover mechanisms and consequences which previously do not seem to have been anticipated.
25#
發(fā)表于 2025-3-25 22:21:29 | 只看該作者
Safeguarding Against the Analog of Antimicrobial-Resistance DevelopmentThis section aims to point to perhaps one of the greatest challenges of all current Covid-19 vaccines altogether. Just as in the previous section, it does not apply to mRNA vaccines alone, although special focus will be given to the latter whenever possible.
26#
發(fā)表于 2025-3-26 03:57:58 | 只看該作者
Scales, Pseudoscales, the Human Factor, and a Way ForwardArguably, mRNA vaccines have led to risks and concerns that previously were not anticipated. Both the vaccine by Pfizer and that by Moderna are now linked to post-vaccination deaths and many adverse health effects
27#
發(fā)表于 2025-3-26 08:09:19 | 只看該作者
28#
發(fā)表于 2025-3-26 12:17:34 | 只看該作者
29#
發(fā)表于 2025-3-26 13:09:22 | 只看該作者
30#
發(fā)表于 2025-3-26 20:50:17 | 只看該作者
https://doi.org/10.1057/9780230251090e of the Covid-19 pandemic in a unique way. Since its emergence during the fall of 2021, it has rapidly spread worldwide and, along with its later subvariants, has soon become responsible for virtually all Covid-19 cases.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-20 17:37
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
大同县| 永昌县| 汤原县| 乳山市| 大名县| 黑河市| 汝城县| 容城县| 东乡族自治县| 当阳市| 南宫市| 保定市| 永平县| 陵川县| 建瓯市| 阿拉善左旗| 巫山县| 高要市| 永嘉县| 米脂县| 安顺市| 尼玛县| 台前县| 新津县| 瓦房店市| 丰县| 高安市| 凤庆县| 夹江县| 原阳县| 青海省| 黄浦区| 新泰市| 平乐县| 紫阳县| 蓝山县| 连城县| 汉源县| 宾阳县| 湘乡市| 宾川县|